Locus Pharmaceuticals has inked a drug discovery deal to put its expertise at computational drug design to work for Ono Pharmaceutical. The molecular target is a protein kinase selected by Ono. Financial and other terms of the agreement were not disclosed.
"We look forward to this multi-year collaboration with Ono, which allows us to apply and leverage all of our internal drug development capabilities as well as our kinase knowledge-base," said H. Joseph Reiser, Ph.D., chairman and CEO of Locus. "We have already demonstrated the power of our computational approaches and proprietary algorithms in our internal kinase programs and in other kinase-related collaborations, so we expect to bring significant value to Ono's efforts against this target."
- take a look at the release on the deal